JP2021169519A5 - - Google Patents

Download PDF

Info

Publication number
JP2021169519A5
JP2021169519A5 JP2021119885A JP2021119885A JP2021169519A5 JP 2021169519 A5 JP2021169519 A5 JP 2021169519A5 JP 2021119885 A JP2021119885 A JP 2021119885A JP 2021119885 A JP2021119885 A JP 2021119885A JP 2021169519 A5 JP2021169519 A5 JP 2021169519A5
Authority
JP
Japan
Prior art keywords
complex
deficiency
side effects
butyl
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021119885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021169519A (ja
Filing date
Publication date
Priority claimed from JP2020018467A external-priority patent/JP7229189B2/ja
Application filed filed Critical
Publication of JP2021169519A publication Critical patent/JP2021169519A/ja
Publication of JP2021169519A5 publication Critical patent/JP2021169519A5/ja
Pending legal-status Critical Current

Links

JP2021119885A 2014-04-08 2021-07-20 新規な細胞透過性サクシネート化合物 Pending JP2021169519A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470190 2014-04-08
DKPA201470190 2014-04-08
JP2020018467A JP7229189B2 (ja) 2014-04-08 2020-02-06 新規な細胞透過性サクシネート化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020018467A Division JP7229189B2 (ja) 2014-04-08 2020-02-06 新規な細胞透過性サクシネート化合物

Publications (2)

Publication Number Publication Date
JP2021169519A JP2021169519A (ja) 2021-10-28
JP2021169519A5 true JP2021169519A5 (cg-RX-API-DMAC7.html) 2021-12-23

Family

ID=58804197

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016561677A Active JP7082861B6 (ja) 2014-04-08 2015-04-08 新規な細胞透過性サクシネート化合物
JP2020018467A Active JP7229189B2 (ja) 2014-04-08 2020-02-06 新規な細胞透過性サクシネート化合物
JP2021119813A Pending JP2021169518A (ja) 2014-04-08 2021-07-20 新規な細胞透過性サクシネート化合物
JP2021119885A Pending JP2021169519A (ja) 2014-04-08 2021-07-20 新規な細胞透過性サクシネート化合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016561677A Active JP7082861B6 (ja) 2014-04-08 2015-04-08 新規な細胞透過性サクシネート化合物
JP2020018467A Active JP7229189B2 (ja) 2014-04-08 2020-02-06 新規な細胞透過性サクシネート化合物
JP2021119813A Pending JP2021169518A (ja) 2014-04-08 2021-07-20 新規な細胞透過性サクシネート化合物

Country Status (25)

Country Link
US (2) US11147789B2 (cg-RX-API-DMAC7.html)
EP (2) EP3391941B1 (cg-RX-API-DMAC7.html)
JP (4) JP7082861B6 (cg-RX-API-DMAC7.html)
KR (1) KR102322543B1 (cg-RX-API-DMAC7.html)
CN (1) CN106458957B (cg-RX-API-DMAC7.html)
AU (2) AU2015243346C9 (cg-RX-API-DMAC7.html)
CA (1) CA2944565C (cg-RX-API-DMAC7.html)
CY (1) CY1120650T1 (cg-RX-API-DMAC7.html)
DK (1) DK3129016T3 (cg-RX-API-DMAC7.html)
EA (1) EA035678B1 (cg-RX-API-DMAC7.html)
ES (2) ES2953522T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181126T1 (cg-RX-API-DMAC7.html)
IL (1) IL247904B (cg-RX-API-DMAC7.html)
LT (2) LT3129016T (cg-RX-API-DMAC7.html)
MA (2) MA44092B1 (cg-RX-API-DMAC7.html)
MX (1) MX378072B (cg-RX-API-DMAC7.html)
PL (1) PL3129016T3 (cg-RX-API-DMAC7.html)
PT (2) PT3129016T (cg-RX-API-DMAC7.html)
RS (1) RS57624B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201607907PA (cg-RX-API-DMAC7.html)
SI (1) SI3129016T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800429T1 (cg-RX-API-DMAC7.html)
TR (1) TR201810411T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015155231A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606608B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106255509A (zh) 2014-04-08 2016-12-21 纽维制药有限公司 用于在归因于线粒体氧化磷酸化的复合体i相关损伤的乳酸性酸中毒或药物诱导的副作用的治疗中应用的琥珀酸酯前药
ES2953522T3 (es) * 2014-04-08 2023-11-14 Abliva Ab Compuestos de succinato novedosos con permeabilidad celular
KR20160143731A (ko) * 2014-04-08 2016-12-14 뉴로바이브 파마슈티컬 에이비 Atp 생산을 증가시키기 위한 숙신산 프로드러그
WO2017060422A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders
WO2017060400A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
WO2017060418A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
WO2017096270A1 (en) 2015-12-03 2017-06-08 The Regents Of The University Of California Methods for treating mitochondrial diseases
EP3863596A4 (en) * 2018-10-11 2022-08-10 Imbria Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF LEBERIAN OPTIC ATROPHY
JP2022504584A (ja) * 2018-10-11 2022-01-13 インブリア ファーマシューティカルズ, インコーポレイテッド Tca回路中間体およびその使用方法
CN109675037B (zh) * 2019-01-25 2021-09-14 南方医科大学 Atp及其受体在制备治疗自闭症药物中的应用
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB756422A (en) * 1950-09-14 1956-09-05 Saint Gobain Esters of urethanes of glycols and the manufacture thereof
NL6806584A (cg-RX-API-DMAC7.html) * 1965-09-20 1968-11-12
FR2265355B1 (cg-RX-API-DMAC7.html) 1974-03-28 1977-11-04 Blum Jean
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
DE4101158C2 (de) * 1991-01-14 1994-06-23 Dainippon Ink & Chemicals Wärmehärtbare Reaktionsharzgemische, Verwendung der erfindungsgemäßen Reaktionsharze zur Herstellung von Formkörpern und Beschichtungen
EP0583480A4 (en) 1992-02-07 1994-03-18 Tsumura & Co Side-effect alleviant.
JPH07331262A (ja) * 1994-05-31 1995-12-19 Tonen Corp パティキュレート低減用添加剤及び該添加剤を用いたディーゼルエンジン用燃料組成物
CN1222139A (zh) * 1996-06-13 1999-07-07 里奥药物制品有限公司 多元醇琥珀酸酯及其药物制剂
GB9612331D0 (en) * 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
WO2000001838A2 (en) 1998-07-02 2000-01-13 The Board Of Regents Of The Leland Stanford Junior University Methods for making polyketides
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
US7727713B2 (en) * 2001-06-20 2010-06-01 Nuevolution A/S Templated molecules and methods for using such molecules
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR100791844B1 (ko) 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
KR101069502B1 (ko) 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
US20120308646A1 (en) * 2007-01-18 2012-12-06 Hesheng Zhang Tetracyclic anthraquinones possessing anti-cancer properties
JP2010522762A (ja) 2007-03-26 2010-07-08 サルトリア・フアーマシユーテイカルズ・エル・エル・シー 糖尿病の治療のための方法及びプロブコール誘導体の組成物
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
JP2014024772A (ja) 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのatp産生能昂進剤
ES2661009T3 (es) 2012-10-05 2018-03-27 Neurovive Pharmaceutical Ab Succinatos protegidos para mejorar la producción de ATP mitocondrial
CN106255509A (zh) 2014-04-08 2016-12-21 纽维制药有限公司 用于在归因于线粒体氧化磷酸化的复合体i相关损伤的乳酸性酸中毒或药物诱导的副作用的治疗中应用的琥珀酸酯前药
ES2953522T3 (es) * 2014-04-08 2023-11-14 Abliva Ab Compuestos de succinato novedosos con permeabilidad celular
KR20160143731A (ko) 2014-04-08 2016-12-14 뉴로바이브 파마슈티컬 에이비 Atp 생산을 증가시키기 위한 숙신산 프로드러그

Similar Documents

Publication Publication Date Title
CN103998035B (zh) 包含格列酮和nrf2激活剂的药物组合物
EP3138838A1 (en) Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
JP2018536641A5 (cg-RX-API-DMAC7.html)
JP2010526831A5 (cg-RX-API-DMAC7.html)
EA030250B1 (ru) Применение 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты и содержащие их фармацевтические композиции
CA2341700A1 (en) Compositions and methods for treatment of mitochondrial diseases
EP3280405B1 (en) Inhibitors and their uses
JP2021527061A5 (cg-RX-API-DMAC7.html)
JP2023529570A5 (cg-RX-API-DMAC7.html)
AU2005295080A1 (en) Compounds and methods of treating insulin resistance and cardiomyopathy
JP7808892B2 (ja) 長鎖化合物およびその使用
WO2021094331A1 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
JP2021527045A5 (cg-RX-API-DMAC7.html)
Nudelman Dimeric drugs
CN114080227B (zh) 包含o-环植物鞘氨醇-1-磷酸酯的用于预防或治疗帕金森氏病的组合物
WO2006003277A1 (fr) Produits biaryl aromatiques, compositions les contenant et utilisation comme medicaments
Muñoz-Torrero Multitarget anti-Alzheimer hybrid compounds: do they work in vivo?
HUT70394A (en) Substituted kynurenines and a process for the preparation of them and pharmaceutical compns. contg. them
WO1998014213A1 (en) Mitochondrial membrane stabilizer
EP1745786A1 (fr) Composés neuroprotecteurs et compositions pharmaceutiques les comprenant
EP2217560B1 (en) Synthetic analogs of sphingolipids
US20090247535A1 (en) Use of ranolazine for non-cardiovascular disorders
JP2024516462A (ja) Pparモジュレーター及びウロリチン誘導体を含む組成物並びにその使用
CA3113071A1 (en) Tca cycle intermediates and methods of use thereof